Clinical Trial: Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07115485) titled 'Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma' on Aug. 04.

Brief Summary: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Study Start Date: Aug. 20

Study Type: INTERVENTIONAL

Condition: Gastric or Gastroesophageal Junction Adenocarcinoma

Intervention: DRUG: HLX43 DOSE 1

HLX43 is an anti-PD-L1 monoclonal antibody conjugated...